Good clinical practice is based on a secure and accurate diagnosis. Poor nutrition is frequently associated with disorders of the liver, and a specific nutrition diagnosis is needed for providing best care and experiencing successful outcome. There is opportunity for better-structured approaches to making secure and consistent nutritional diagnoses in patients with liver disease. Nutrition is the set of integrated processes by which cells, tissues, organs and the whole body acquire the energy and nutrients to retain normal structure and perform the required functions. At the level of the whole body, this is achieved through dietary supply and the capacity of the body to transform the substrates and cofactors necessary for metabolism. All of these domains (diet, metabolic capacity, activity of the microbiome, body composition and the level of demand for energy and nutrients) are influenced by levels of physical activity and can vary according to physiological and pathological disease states. The liver plays a central role in establishing and maintaining these regulated processes. Its capacity to achieve and maintain these functional capabilities is established during one's early life. When these capabilities are exceeded and the ability to maintain the milieu interieur is compromised, ill-health supervenes. Stress tests that assess flow through gateway pathways can be used to determine the maximal capacity and functional reserve for critical functions. The inability of the liver to reliably integrate body lipid metabolism and the accumulation of abnormal lipid are obvious manifestations of impaired regulation both in situations of weight loss, for example, the fatty liver of severe malnutrition, and in situations of energy excess, as in non-alcoholic fatty liver disease. The use of stable isotopic probes and the more recent definition of the variability in the metabolome in different nutritional and pathological states indicate the great potential for clinical tools that would enable a more precise nutritional diagnosis, but these require systematic investigation and application. For the present, approaches that place emphasis on being able to control the metabolic state without exposing the liver to unnecessary metabolic stress remain the basis for successful nutritional support.

Keywords:
Reductive adaptation, Expansive adaptation, Kupffer cell, Fructose, Copper, Glycine
1.
Jackson AA, Wootton SA, Wiseman M: Nature, purpose and implications of research in nutrition; in Lovegrove JA, Hodson L, Sharma S, Lanham-New SA (eds): Nutrition Research Methodologies. John Wiley & Sons, Ltd., 2015.
2.
Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K: Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 2011;26:30-46.
3.
Wiliams CD: Kwashiorkor a nutritional disease of children associated with a maize diet. Lancet 1935;2:1151-1152.
4.
Waterlow JC: Fatty Liver Disease in Infants in the British West Indies. Medical Research Council, Special Report Series 263. London, HMSO, 1948.
5.
Jahoor F, Jackson AA: Hepatic function in rats with dietary-induced fatty liver, as measured by the uptake of indocyanine green. Br J Nutr 1982;47:391-397.
6.
Kerr DS, Stevens MC, Robinson HM: Fasting metabolism in infants. I. Effect of severe undernutrition on energy and protein utilization. Metabolism 1978;27:411-435.
7.
Kerr DS, Stevens MC, Picou DI: Fasting metabolism in infants: II. the effect of severe undernutrition and infusion of alanine on glucose production estimated with U-13C-glucose. Metabolism 1978;27:831-848.
8.
Selye H: The Story of the Adaptation Syndrome. Montreal, Acta Inc., 1952.
9.
Selye H: Forty years of stress research: principal remaining problems and misconceptions. Can Med Assoc J 1976;115:53-56.
10.
Sinclair M, Gow PJ, Grossmann M, Angus PW: Review article: sarcopenia in cirrhosis - aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther 2016;43:765-777.
11.
Kappus MR, Mendoza MS, Nguyen D, Medici V, McClave SA: Sarcopenia in patients with chronic liver disease: can it be altered by diet and exercise? Curr Gastroenterol Rep 2016;18:43.
12.
Dasarathy S, Merli M: Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016;65:1232-1244.
13.
Jackson AA: The glycine story. Eur J Clin Nutr 1991;45:59-65.
14.
Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, Bedogni G: Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;11:1066-1070.
15.
Parker HM, Johnson NA, Burdon CA, et al: Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951.
16.
Doherty JF, Golden MH, Brooks SE: Peroxisomes and the fatty liver of malnutrition: an hypothesis. Am J Clin Nutr 1991;54:674-677.
17.
Brooks SE, Goldon MH, Taylor E: Hepatic ultrastructure in children with protein-energy malnutrition. West Indian Med J 1992;41:139-145.
18.
Brooks SE, Doherty JF, Golden MH: Peroxisomes and the hepatic pathology of childhood malnutrition. West Indian Med J 1994;43:15-17.
19.
Jackson AA, Soares MJ, Grove G, Waterlow JC: Enrichment in urinary ammonia and urea with hourly oral doses of [15N]glycine: evidence for a step function and a circadian rhythm in protein turnover. Clin Sci 1997;93:265-271.
20.
Ohsumi Y: Historical landmarks of autophagy research. Cell Res 2014;24:9-23.
21.
Jackson AA: Salvage of urea-nitrogen in the large bowel: functional significance in metabolic control and adaptation. Biochem Soc Trans 1998;26:231-236.
22.
Jackson AA: Salvage of urea-nitrogen and protein requirements. Proc Nutr Soc 1995;54:535-547.
23.
Waterlow JC: The mysteries of nitrogen balance. Nutr Res Rev 1999;12:25-54.
24.
Jackson AA: Severe malnutrition; in Warrell DA, Cox TM, Firth JD (eds): Oxford Textbook of Medicine, ed 5. Oxford University Press, 2015. www.oxfordmedicine.com.
25.
Grimble RF: Nutritional modulation of cytokine biology. Nutrition 1998;14:634-640.
26.
Grimble RF: Modification of the inflammatory aspects of immune function by nutrients. Nutrition Research 1998;18:1297-1317.
27.
World Health Organization: Management of Severe Malnutrition: A Manual for Physicians and Other Senior Health Workers. Geneva, WHO, 1999. http://whqlibdoc.who.int/hq/1999/a57361.pdf.
28.
Sica A, Invernizzi P, Mantovani A: Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014;59:2034-2042.
29.
Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat A, Lotersztajn S, Pavoine C: M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014;59:130-142.
30.
Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H: Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Ann Hepatol 2014;13:489-495.
31.
Thurman RG, Schemmer P, Zhong Z, Bunzendahl H, von Frankenberg M, Lemasters JJ: Kupffer cell-dependent reperfusion injury in liver transplantation: new clinically relevant use of glycine. Langenbecks Arch Chir Suppl Kongressbd 1998;115:185-190.
32.
Wheeler MD, Ikejema K, Enomoto N, Stacklewitz RF, Seabra V, Zhong Z, Yin M, Schemmer P, Rose ML, Rusyn I, Bradford B, Thurman RG: Glycine: a new anti-inflammatory immunonutrient. Cell Mol Life Sci 1999;56:843-856.
33.
Rose ML, Rusyn I, Bojes HK, Belyea J, Cattley RC, Thurman RG: Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res 2000;448:179-192.
34.
Ikejima K, Iimuro Y, Forman DT, Thurman RG: A diet containing glycine improves survival in endotoxin shock in the rat. Am J Physiol 1996;271(1 pt 1):G97-G103.
35.
Xu FL, You HB, Li XH, Chen XF, Liu ZJ, Gong JP: Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells. Am J Surg 2008;196:139-148.
36.
Petrat F, Boengler K, Schulz R, de Groot H: Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge. Br J Pharmacol 2012;165:2059-2072.
37.
Jackson AA, Persaud C, Meakins TS, Bundy R: Urinary excretion of 5-L-oxoproline (pyroglutamic acid) is increased in normal adults consuming vegetarian or low protein diets. J Nutr 1996;126:2813-2822.
38.
Meakins TS, Persaud C, Jackson AA: Dietary supplementation with L-methionine impairs the utilization of urea-nitrogen and increases 5-L-oxoprolinuria in normal women consuming a low protein diet. J Nutr 1998;128:720-727.
39.
Jackson AA, Phillips G, McClelland I, Jahoor F: Synthesis of hepatic secretory proteins in normal adults consuming a diet marginally adequate in protein. Am J Physiol Gastrointest Liver Physiol 2001;281:G1179-G1187.
40.
Scientific Advisory Committee on Nutrition: Carbohydrates and Health. The Stationery Office Limited, 2015.
41.
Scientific Advisory Committee on Nutrition: The Nutritional Wellbeing of the British Population. The Stationery Office Limited, 2008.
42.
Reiser S, Smith JC Jr, Mertz W, Holbrook JT, Scholfield DJ, Powell AS, Canfield WK, Canary JJ: Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am J Clin Nutr 1985;42:242-251.
43.
Spruss A, Bergheim I: Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009;20:657-662.
44.
Samuel VT: Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab 2011;22:60-65.
45.
Klevay LM: IHD from copper deficiency: a unified theory. Nutr Res Rev 2016;29:172-179.
46.
Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C: Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007;18:184-195.
47.
Schütte K, Tippelt B, Schulz C, Röhl FW, Feneberg A, Seidensticker R, Arend J, Malfertheiner P: Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 2015;34:1122-1127.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.